纽约（路透社健康经济日报）12月21日电—据《变态反应，关节炎及免疫学年鉴》杂志11月刊一篇另据，舌下减敏本品（SLIT）病患绒毛诱发的呼吸道皮肤病成效较低。“能用SLIT减少哮喘的并发症及本品储蓄，减低社会生活经济财政负担，”意大利Genoa大学Giovanni Passalacqua助手知道。“先前已经有强化注射本品减低社会生活财政负担，但这是首次对实用本品（SLIT）顺利进行严格审计的结果。”Passalacqua助手及其同事们对绒毛诱发的荨麻疹哮喘和关节炎治果顺利进行研究，审计能用SLIT结合规格病患及分开能用规格病患的费用及。研究人员另据，SLIT使63.1%的病症症状加强，并预防病态51.8%的病症出现关节炎，而分开应用领域规格本品仅仅使23.2%的病症症状加强，预防病态28.9%的病症出现关节炎。而且同规格病患相比，SLIT的直接及间接总成本均降低：SLIT病症病患的总体总成本高于国家卫生保健种系统假设的4年内分开本品病患总成本，并且高于社会生活公众假设的2年内分开本品病患总成本。“SLIT并不能毕竟强化注射本品的竞争对手，” Passalacqua助手解释知道，“而是将其作为病患作法的另一选择。它仅有的优点在于其匹配的安全病态和病症的所致给予病态。”“SLIT在美国并未正式应用领域，尽管一些变态反应专家应用领域它（并且取得了满意的结果），” Passalacqua助手知道。“欧洲情况显然不同，SLIT在很多国家中都广泛应用领域（如意大利，德国，德国，安达卢西亚，葡萄牙，希腊及克罗地亚）。”当前的问题是SLIT并未取得FDA的批准，“Passalacqua助手知道明道。“受到FDA赞同的医学研究正在顺利进行中都，并有望取得批准。” Sublingual Immunotherapy Cost-Effective for Pollen-Induced AllergyBy Will Boggs, MDNEW YORK (Reuters Health) Dec 21 - Sublingual immunotherapy (SLIT) is cost-effective for treating s with pollen-induced respiratory allergy, according to a report in the November Annals of Allergy, Asthma & Immunology."The use of SLIT leads to a socio-economic sings by reducing the comorbidities of rhinitis and drug consumption," Dr. Giovanni Passalacqua from University of Genoa, Italy told Reuters Health. "This fact has been previously envisaged also for injection IT, but this is the first rigorous assessment made by means of a validated economic model."Dr. Passalacqua and colleagues' study was designed to evaluate the costs and consequences of using SLIT in association with standard treatment compared with standard treatment alone in young s with pollen-induced allergic rhinitis and asthma.SLIT improved symptoms of 63.1% of patients and prevented asthma in 51.8% of patients, the authors report, compared with 23.2% and 28.9%, respectively, of patients receiving standard treatment.Compared with standard treatment, SLIT resulted in lower direct and indirect expenses, the researchers note.According to the results, the overall cost of treatment for SLIT patients drops below that for patients receiving only drugs at year 4 from the National Healthcare System perspective and at year 2 from the societal perspective."SLIT is not to be intended as an antagonist of injection IT," Dr. Passalacqua explained, "rather as an additional therapeutic option. Its best advantage is the optimal safety profile and the good acceptance by the patients.""SLIT is not officially in use in the USA, although some allergists utilize it (with satisfactory results)," Dr. Passalacqua said. "In Europe the situation is completely different, and SLIT is widely used in many countries (e.g., Italy, Germany, France, Spain, Portugal, Greece, and Hungary).""The problem is formal, due to the fact that SLIT has not the approval of the FDA," Dr. Passalacqua added. "Clinical studies endorsed by the FDA are currently ongoing to get the approval."Ann Allergy Asthma Immunol 2006;97:615-621.
总编辑：蓝色幻想
总编辑： 张靖相关新闻
相关问答
